epirubicin has been researched along with Left Ventricular Hypertrophy in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Han, Q; Hu, R; Irwin, DM; Li, H; Man, Z; Mao, Y; Niu, G; Tan, H; Wang, X; Zhang, J; Zhang, Q; Zhang, X | 1 |
1 other study(ies) available for epirubicin and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
Xinmailong mitigated epirubicin-induced cardiotoxicity via inhibiting autophagy.
Topics: Animals; Autophagy; Cardiotonic Agents; Cardiotoxicity; Collagen; Disease Models, Animal; Drugs, Chinese Herbal; Epirubicin; Extracellular Signal-Regulated MAP Kinases; Fibrosis; Gene Expression Regulation; Heart Diseases; Hypertrophy, Left Ventricular; Male; Matrix Metalloproteinase 9; Myocardium; p38 Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; Rats, Sprague-Dawley; RNA, Messenger; Signal Transduction; Stroke Volume; Time Factors; Tissue Inhibitor of Metalloproteinase-4; Tissue Inhibitor of Metalloproteinases; Transforming Growth Factor beta1; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2016 |